Gamida Cell Ltd. (GMDA) Stock Price & Growth Analysis

You have successfully sign out

Company Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

N/A(N/A)

Number of analyst

N/A

Earnings Growth

YoY

Current

Estimates

Q2.22

N/A

-0.31
vs -0.42

Q3.22

N/A

-0.29
vs -0.33

Q4.22

N/A

-0.29
vs -0.34

Q1.23

N/A

-0.27
vs -0.34

Q2.23

N/A

-0.31
vs -0.31

Q3.23

N/A

-0.01
vs -0.29

Q4.23

N/A

-0.04
vs -0.29

Q1.24

+148%

0.13
vs -0.27

Q2.24

N/A

-0.14
vs -0.31

Q3.24

N/A

-0.15
vs -0.01

Sales Growth

YoY

Current

Estimates

Q2.22

NA vs NA

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

673K vs NA

Q4.23

1.1M vs NA

Q1.24

890K vs NA

Q2.24

3.8M vs NA

Q3.24

+522%

4.2M vs 673K

Return on Equity

QoQ

Q4.21

-70%

-0.70
vs -0.43

Q1.22

-85%

-0.85
vs -0.70

Q2.22

-466%

-4.66
vs -0.85

Q3.22

-137%

-1.37
vs -4.66

Q4.22

+540%

5.4
vs -1.37

Q1.23

+145%

1.45
vs 5.4

Q2.23

+123%

1.23
vs 1.45

Q3.23

-398%

-3.98
vs 1.23

Q4.23

+300%

3
vs -3.98

Q1.24

-106%

-1.06
vs 3

Institutionnal Ownership

QoQ

Q4.21

64
vs 73

-12%

Q1.22

61
vs 64

-5%

Q2.22

55
vs 61

-10%

Q3.22

60
vs 55

Q4.22

58
vs 60

-3%

Q1.23

49
vs 58

-16%

Q2.23

69
vs 49

41%

Q3.23

65
vs 69

-6%

Q4.23

57
vs 65

-12%

Q1.24

54
vs 57

-5%

Earnings Growth

Quote Panel

Updated August 18, 2025

1W % 1M % 3M 0.00 % 1Y 0.00 %

Key Metrics

Market Cap
4.34M
Shares Outstanding
132.64M
Share in Float
120.38M
Dividende
0

Earning Date
No Data
Price Target
0.0327
Average Volume
21.71M
Beta
1.032

Range
0.0327-0.0395
Industry
Biotechnology
Website
https://www.gamida-cell.com
Sector
Healthcare

Forecast

$231M

25844%

2025-Revenue

$0.39

200%

2025-EPS

$139M

677%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

N/A(N/A)

Number of analyst

N/A

Last analyst upgrade/downgrade

No Data Available

Gamida Cell Ltd.

GMDA

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

Biotechnology

Next Earning date - N/A

0.03USD

0.00 ( 0.00%)

After-hours 0.00$

-0.03 (-100.00%)

Market Closed (as of Jun 17, 20:00 EDT)

Relative Strenght

Volume Buzz

-12%

Earning Acce

Dist 52w H.

17%

Relative Strength

GMDA

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Earnings Growth

YoY

Current

Estimates

Q2.22

N/A

-0.31
vs -0.42

Q3.22

N/A

-0.29
vs -0.33

Q4.22

N/A

-0.29
vs -0.34

Q1.23

N/A

-0.27
vs -0.34

Q2.23

N/A

-0.31
vs -0.31

Q3.23

N/A

-0.01
vs -0.29

Q4.23

N/A

-0.04
vs -0.29

Q1.24

+148%

0.13
vs -0.27

Q2.24

N/A

-0.14
vs -0.31

Q3.24

N/A

-0.15
vs -0.01

Sales Growth

YoY

Current

Estimates

Q2.22

NA vs NA

Q3.22

NA vs NA

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

673K vs NA

Q4.23

1.1M vs NA

Q1.24

890K vs NA

Q2.24

3.8M vs NA

Q3.24

+522%

4.2M vs 673K

Return on Equity

QoQ

Q4.21

-70%

-0.70
vs -0.43

Q1.22

-85%

-0.85
vs -0.70

Q2.22

-466%

-4.66
vs -0.85

Q3.22

-137%

-1.37
vs -4.66

Q4.22

+540%

5.4
vs -1.37

Q1.23

+145%

1.45
vs 5.4

Q2.23

+123%

1.23
vs 1.45

Q3.23

-398%

-3.98
vs 1.23

Q4.23

+300%

3
vs -3.98

Q1.24

-106%

-1.06
vs 3

Institutionnal Ownership

QoQ

Q4.21

64
vs 73

-12%

Q1.22

61
vs 64

-5%

Q2.22

55
vs 61

-10%

Q3.22

60
vs 55

Q4.22

58
vs 60

-3%

Q1.23

49
vs 58

-16%

Q2.23

69
vs 49

41%

Q3.23

65
vs 69

-6%

Q4.23

57
vs 65

-12%

Q1.24

54
vs 57

-5%

Earnings Growth

Fundamentals

N/A

P/E Ratio

2.43x

P/S Ratio

N/Ax

P/B Ratio

N/A

Debt/Equity

-3531.2%

Net Margin

$-0.8

EPS

How GMDA compares to sector?

P/E Ratio

Company Description

0.03USD

N/A

2.43x

N/Ax

N/A

-3531.2%

$-0.8

$231M

$0.39

$139M

Earnings Growth

Latest News

Latest News

Latest News

$231M

$0.39

$139M

Company Description

0.03USD

Earnings Growth

N/A

2.43x

N/Ax

N/A

-3531.2%

$-0.8